Company Overview
Attovia Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops biotherapeutics for immune-mediated diseases in the United States. The company provides ATTOBODY, a biparatopic biologics platform designed to deliver improved treatments. The company's products include ATTO-1310, a novel ATTOBODY-based Fc-fusion protein therapeutic that inhibits IL-31; developed for the treatment of chronic pruritic diseases such as CPUO, high-itch AD, cholestatic pruritus, and CKD-aP; ATTO-2306, an ATTOBODY-based, half-life-extended immunoglobulin G (IgG)-fusion protein therapeutic that inhibits IL-13 and IL-31; developed for the treatment of AD and other immune-mediated skin diseases, such as CSU and PN; and ATTO-1091, a trispecific ATTOBODY-based Fc-fusion protein therapeutic that inhibits TL1A, IL-23, and integrin a4ß7; developed for IBD a chronic immune-mediated condition characterized by persistent inflammation of the gastrointestinal tract, includes ulcerative colitis (UC) and crohn's disease (CD). The company was incorporated in 2022 and is based in San Carlos, California.
Why Investors Should Care
Generates a return on equity of 56.4%, reflecting efficient use of shareholder capital.
Recent Developments
- 5-Year Trend Long-term compounding — profit CAGR -52.3%.
Growth & Price Performance
Compounded Profit Growth
| 5 Years: | -52.33% |
| 1 Year: | - |
Stock Price Performance
| 1 Year: | +8.04% |
| 6 Months: | - |
| 3 Months: | - |
| 1 Month: | +17.30% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- RSI (14)44.15 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Strong return on equity of 56.4%.
CONS
- Earnings shrank at -52.3% CAGR over 5 years.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | ATTO Attovia Therapeutics, Inc. PHARMA | 23.66 | -14.43 | $1.08B | 0.00% | -43.36% | 56.43% | - | -52.33% |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2025 | Mar 2026 |
|---|---|---|
| Revenue | 0 | 0 |
| Cost of Revenue | - | - |
| Gross Profit | - | - |
| Operating Expenses | 16.10M | 19.95M |
| Operating Income | -16.10M | -19.95M |
| EBITDA | -15.96M | -19.71M |
| Interest Expense | - | - |
| Pretax Income | -15.15M | -18.66M |
| Tax Provision | - | - |
| Net Income | -15.15M | -18.66M |
| Diluted EPS | -0.60 | -0.73 |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2024 | Dec 2025 |
|---|---|---|
| Revenue | 0 | 1.35M |
| Cost of Revenue | - | - |
| Gross Profit | - | - |
| Operating Expenses | 41.55M | 68.51M |
| Operating Income | -41.55M | -67.16M |
| EBITDA | -41.24M | -66.36M |
| Interest Expense | - | - |
| Pretax Income | -39.80M | -60.63M |
| Tax Provision | - | - |
| Net Income | -39.80M | -60.63M |
| Diluted EPS | -1.75 | -2.37 |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2024 | Dec 2025 |
|---|---|---|
| Total Assets | 76.72M | 165.89M |
| Current Assets | 72.48M | 156.29M |
| Cash & Equivalents | 30.63M | 40.19M |
| Inventory | - | - |
| Receivables | 125.00K | 900.00K |
| Total Liabilities | 123.54M | 273.33M |
| Current Liabilities | 7.72M | 11.01M |
| Long Term Debt | - | - |
| Total Debt | 0 | 5.26M |
| Total Equity | -46.83M | -107.44M |
| Shares Outstanding | - | - |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2024 | Dec 2025 |
|---|---|---|
| Operating Cash Flow | -35.03M | -59.20M |
| Investing Cash Flow | -39.80M | -73.45M |
| Financing Cash Flow | 82.75M | 142.01M |
| Capital Expenditure | -1.77M | -2.31M |
| Free Cash Flow | -36.81M | -61.51M |
| Net Change in Cash | 7.91M | 9.36M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2024 | Dec 2025 |
|---|---|---|
| Gross Margin % | - | - |
| Operating Margin % | - | -4,974.7% |
| Net Margin % | - | -4,490.9% |
| ROE % | 85.0% | 56.4% |
| ROCE % | -60.2% | -43.4% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for ATTO
Two investor events are on Attovia’s September calendar - Stock Titan
<a href="https://news.google.com/rss/articles/CBMisAFBVV95cUxQZDFwNWlSQlAxUTZWUVVld0RCVGZ2cW1iSnRUelZKWVpORWNaQWVBZUlzcVlmZUthMDlQZDNmSnpWSTRmYXJHZTBUbmN6Q3NFRGE5X00zZ0xTVGVGWWtLZ3hsdUNCNFQwYzNBUkpPSGF4U3NlbndGQU1OZHBRdHVwb1cxLWFPYjBicHd3MV…
Attovia Therapeutics, Inc. (ATTO) Stock Price, News, Earnings & Company Profile - RTTNews
<a href="https://news.google.com/rss/articles/CBMieEFVX3lxTFBpM3BLaDVqV0drQkE2cDlFbVZrZ1lKc2NCZy12YXdJZVdnbmVKQU80Z3djWnlSRW82Y0tRUDhWZ3R2YUFKQVBIR0s2dVNIN0JYbnpWTHQwaGE5YzdNZ3J5Sjc1Mi1UR0pfRUdtd3hBTUZyUUpRdjJTbg?oc=5" target="_blank">Attov…
symbol__ Stock Quote Price and Forecast - CNN
<a href="https://news.google.com/rss/articles/CBMiUEFVX3lxTFBfdXpJUDJydVJvaV9pc2RIeXQ1WVVoQU41WUF4emxtMndfalRCbGpLejlDdWFTYnI5NXZmcXh6akUwaGlsLVpyY3czMTd0U0VQ?oc=5" target="_blank">symbol__ Stock Quote Price and Forecast</a> <fon…
Attovia Therapeutics, Inc.'s (NASDAQ:ATTO) Quiet Period To End on September 14th - marketbeat.com
<a href="https://news.google.com/rss/articles/CBMi0gFBVV95cUxNU0Ziajd1d09qbXRhbkpERVVOYnRrOGZmSTlIdFBVcnl0SGdsYUJaSXBidVRSODFtSVFDaWR6ekVJUTBIS3l6VEpWdmNjQjdhRkJ6cU1BMnNTY2lyNU5VRTBmb2I1WHcxdDY2bGVBRUNPUmZWbzdxeGNjYWh0NUJpMHFHeVc4VTVkcmJHek…
Attovia Therapeutics to Participate in Upcoming Citi and Morgan Stanley Investor Conferences - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMiwwFBVV95cUxQbG05dEh3M1BVZkxydFBXWUhYN3JKc21KV1R4V3FUX3NGQjdTQUtFSkh3UWlOZUtMZEdfNk5RalBIOFlDSVBzRlF6b1oyVm5hVWRaYTBuWjlxdWFuNHpFMk9LajM2aDNUc01FOFFaR1YxOEpMMjZ4bEFyVTBfSFV2WV9RUTZ6YlptMEc5Ml…
Analysts Offer Insights on NA Companies: Attovia Therapeutics, Inc. (ATTO) and Navan, Inc. Class A (NAVN) - The Globe and Mail
<a href="https://news.google.com/rss/articles/CBMiiAJBVV95cUxQOWZhNDJlTXBlaEJoVjdzLXlNOXRNaDBRVG5LV1dYT09XT2o3aDlvT0gxakZNY0dLd3NmT1ZsbDlLZ2YwcDRmdVRJbFFTdkUzQ1J1ZmFfQkIwZVp3T0lJaU95RWQ4QmxXaThzcDFGaTZEcUtjZHJKYUw4TGlKNk5fR3F4UE5tYTdnMWlkUX…
ATTO — Frequently Asked Questions
What is the current share price of Attovia Therapeutics, Inc. (ATTO)?
As of 2026-09-19 21:16 PDT, Attovia Therapeutics, Inc. (ATTO) trades at $23.66 on NasdaqGM. Its 52-week range is $18.06 to $25.55.
What is the market capitalisation of ATTO?
Attovia Therapeutics, Inc. (ATTO) has a market capitalisation of $1.08B on NasdaqGM.
What is the P/E ratio of ATTO?
ATTO trades at a trailing price-to-earnings (P/E) ratio of -14.43. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is -0.71.
What is the return on equity (ROE) of ATTO?
ATTO has a return on equity (ROE) of 56.43%. Its return on capital employed (ROCE) is -43.36%.
Is ATTO a good stock to buy?
This page provides a data-driven analysis of Attovia Therapeutics, Inc. (ATTO), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.